- 10
- 1 669
Foresight Diagnostics
Приєднався 14 гру 2023
Advancing Precision Medicine in Lymphoma with ctDNA-MRD - presentation by Dr. Mark Roschewski (NCI)
In this recorded presentation from the Advancing Precision Medicine conference (November 1, 2024), Dr. Mark Roschewski, Clinical Director of the Lymphoid Malignancies Branch at the NCI's Center for Cancer Research, discusses the promising applications of ultra-sensitive ctDNA-MRD detection to drive more personalized treatment paradigms in lymphoma.
At the time of this presentation Foresight CLARITY is a lab-developed test for the detection of minimal residual disease (MRD) in B-cell lymphoma. This test is for research use only and is not intended for use in diagnostic procedures.
At the time of this presentation Foresight CLARITY is a lab-developed test for the detection of minimal residual disease (MRD) in B-cell lymphoma. This test is for research use only and is not intended for use in diagnostic procedures.
Переглядів: 87
Відео
Foresight CLARITY MRD - Detect relapse 200 days earlier
Переглядів 13Місяць тому
Why is ultra-sensitive MRD detection by Foresight CLARITY so powerful? With the ability to detect relapse risk up to 200 days before it occurs (detected via imaging), clinicians may be able to intervene with more effective treatment strategies. Learn more in our video. Foresight CLARITY MRD is for research use only. Not for use in diagnostic procedures.
Foresight Diagnostics - Our central CLIA lab for clinical trials
Переглядів 3322 місяці тому
Learn more about Foresight Diagnostics' CLIA-certified central lab built to support regulated biopharma and academic clinical trials.
Foresight CLARITY™ MRD Detection, powered by PhasED-Seq™
Переглядів 542 місяці тому
Foresight Diagnostics presents Foresight CLARITY, our ultra-sensitive minimal residual disease (MRD) detection platform, powered by our proprietary PhasED-Seq technology. We are on a mission to improve the lives of cancer patients worldwide through innovative diagnostics.
Webinar - Rethinking therapeutic response assessment in lymphoma clinical trials (Mar 7 2024)
Переглядів 1575 місяців тому
Webinar - Rethinking therapeutic response assessment in lymphoma clinical trials (Mar 7 2024)
Early and sustained ctDNA response in lonca for 3L DLBCL - Dr. David Kurtz, ASH 2023
Переглядів 15611 місяців тому
Dr. David Kurtz (Stanford University, Foresight Diagnostics) summarizes one of the studies presented at the American Society of Hematology (ASH) Annual Conference in 2023 that analyzed whether PhasED-Seq MRD could predict early and sustained response to lonca 3L DLBCL therapy in a study of the LOTUS-2 trial . In this video Dr. Kurtz discusses the study objective, methodology, and key results. F...
PhasED-Seq as an early outcome predictor for liso-cel therapy in DLBCL - Dr. Ash Alizadeh, ASH 2023
Переглядів 22811 місяців тому
Dr. Ash Alizadeh (Stanford University) summarizes one of the studies presented at the American Society of Hematology (ASH) Annual Conference in 2023 that analyzed whether PhasED-Seq MRD could predict response to liso-cel 2L DLBCL therapy in a sub-study of the TRANSFORM Phase 3 registrational trial. In this video Dr. Alizadeh discusses the study objective, methodology, and key results. Figures a...
Optimizing ctDNA limits of detection for DLBCL during 1L therapy - Dr. Jordan Goldstein, ASH 2023
Переглядів 22011 місяців тому
Dr. Jordan Goldstein (Stanford University) summarizes one of the studies presented at the American Society of Hematology (ASH) Annual Conference in 2023 that compared the performance of ctDNA assays at various time points and at various limits of detection to determine the optimal sensitivity level that accurately predicts progression-free survival following first-line therapy in DLBCL. In this...
Prospective real-world study on the utility of PhasED-Seq MRD - Dr. Brian Sworder, ASH 2023
Переглядів 16811 місяців тому
Dr. Brian Sworder (UC Irvine) summarizes one of the studies presented at the American Society of Hematology (ASH) Annual Conference in 2023 that compared PhasED-Seq MRD vs. PET/CT to predict response following curative intent induction therapy in patients with diffuse large B-cell lymphoma (DLBCL). In this video Dr. Sworder discusses the study objective, methodology, and key results. Figures an...
Landmark comparison of PhasED-Seq ctDNA vs. singular PET/CT scan - Dr. Mark Roschewski, ASH 2023
Переглядів 27011 місяців тому
Dr. Mark Roschewski (NIH) summarizes one of the studies presented at the American Society of Hematology (ASH) Annual Conference in 2023 that compared PhasED-Seq ultra-sensitive ctDNA vs. singular PET/CT scan for end-of-treatment response assessment after frontline therapy for aggressive B-cell lymphoma. In this video Dr. Roschewski discusses the study objective, methodology, and key results. Fi...
Skmodarok 123 Sk
'PromoSM'